Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company ...
Company presentation scheduled on Tuesday, March 4th at 9:10am ET –– EyePoint to provide enrollment update for ongoing DURAVYU™ Phase 3 pivotal ...
CAMBRIDGE, Mass., February 25, 2025--2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team ...
Aktis Oncology, an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results